I agree Kevin. The price drop yesterday prompted by a weak article is clearly manipulation. I added on the drop as IMHO the manipulation is a sign that the announcement is near.
I hope so mike! Today's performance was pathetic. 6% off the index. This silence is getting OLD and PLAYED out.
Make no mistake about it..... that was one of the most pathetic performances by this stock in some time. Biotech index up 4% and we are down 2% We have had bad days in the recent past driven by market biotech index moves but this was just pathetic today. 6% differential. People can say be patient until they are blue in the face but at some point its time for results!!?
We seem to be having some mild manipulation today. Not of the magnitude you are talking about but we have broken to the downside compared to the biotech indexes today.
I was giving two hypothetical extremes, simply indicating that either extreme is still potentially profitable.
If you can see into the future glue please let us know exactly whats going to happen?
They allowed them to include the graphs showing PK/PD profile that is clear as day to any scientist or physician. One of the post marketing studies, when completed will allow them to make this claim in the label. Regarding hypoglycemia there is nothing to prevent reps from directing docs to reference published studies showing hypoglycemia benefit.
I'm ready for news last week believe me! I have to believe the silence is a good thing.
I too am impatient at this point keven.
As I see it we have two extremes. One one extreme we have immediate gratification: buyout 27.50 a share.
On the other extreme we have go it alone mnkd rough times in the near term but possibly 100.00 a share if launch is completed on a go it alone basis. I calculate approx 25% dilution to go it alone. Long term anything north of 12.50 a share is profitable.
For the record I prefer scenario one and immediate gratification. It is my hope that it is scenario one combined with splitting off technosphere into a stand alone company that is dragging the process out.
Good luck to all longs.
Though I regularly discount Novo and LLY as partners due to the fact that they would first have to erode their own products to make Afrezza successful, it is important to note that insulin IS the raw material for Afrezza.
If they aggressively marketed Afrezza for type II and not type I maybe they could make it work. Couple this with the fact that they would recover some lost revenue by providing the insulin?? INHO NOVO has the more aggressive and forward thinking CEO.
However LLY is the pioneer historically in the insulin market. Just speculation but what else do we have at this point?
Hey Kevin, please correct me if I am wrong but didn't AMLN also handsomly award stock to its executives preceeding its ultimate buyout?
I realize of course that I am being impatient but....... F...... lets announce something already?
Greenhill has been on the job for almost a year. Lets get this done!!!
Over-lay the IBB indes with MNKD the last five days..... almost indentical. I am however seeing a bit of manipulation specific to mnkd.
I'm telling you its the YELLEN effect. This is general pressure from the biotech index sell off currently under way.
If you ware smart you will take this as an opp to add. This had nothing to do with MNKD.
Will still be apparent today..... at least in the early going. How long it will last who knows?
Smart investors look for situations where macro (index) factors drag down the stock price of companies with great things on the near horizon.
I took a nibble yesterday..... will look to add more in the coming days.